A device to remove harmful hemoglobin from blood during certain medical treatments.
Hemoadsorption Device for Selective Removal of Cell-Free Plasma Hemoglobin During Extracorporeal Therapies.
This study is testing a new device that helps clean harmful hemoglobin from the blood during certain medical treatments, like heart surgery, to help prevent kidney problems and improve recovery for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10696056 on NIH RePORTER |
What this research studies
This research focuses on developing a new device designed to remove cell-free plasma hemoglobin from the blood during extracorporeal therapies like cardiopulmonary bypass and extracorporeal membrane oxygenation. These therapies are often used in critical care settings but can lead to complications such as acute kidney injury due to hemolysis. The device utilizes a specialized bead-based matrix that binds to and removes the harmful hemoglobin, potentially improving patient outcomes during these procedures. Preliminary studies have shown promise in the device's ability to effectively filter hemoglobin from blood.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with conditions requiring extracorporeal therapies, particularly those at risk for acute kidney injury.
Not a fit: Patients who do not require extracorporeal therapies or those with conditions unrelated to hemolysis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce complications and improve recovery times for patients undergoing extracorporeal therapies.
How similar studies have performed: Other research has shown success with similar hemoadsorption techniques, indicating potential for this novel approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Kim-Campbell, Nahmah — University of Pittsburgh at Pittsburgh
- Study coordinator: Kim-Campbell, Nahmah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.